A study combining LUM with CDDP + gemcitabine in a breast cancer in vivo PDX model, found the triple combination resulted in a complete response, whereas LUM as a monotherapy and CDDP + gemcitabine as a dual-therapy did not halt disease progression67. The gene discussed is LUM; the disease is breast carcinoma.